What does a back injury in high school, a Stanford pig lab, and a cardiac patient with pancreatic cancer have in common? They all played a role in sending Shaun Bagai on a path that is now changing how we deliver chemotherapy to some of the hardest-to-treat tumors in the body.
Shaun Bagai is the CEO of RenovoRx, the company behind the RenovoCath — an FDA-cleared device that uses Trans Arterial Micro Perfusion (TAMP) to deliver high concentrations of chemotherapy directly to tumors that are poorly connected to the systemic circulation, dramatically reducing side effects and improving survival in locally advanced pancreatic cancer. In this episode, Shaun walks us through how he discovered MedTech almost by accident, why he walked away from medical school after getting in, and the leadership philosophy — built on humility, data, and "beautiful friction" — that has sustained him through 11+ years of building one of the most innovative cancer therapy companies in the industry.
Whether you're a founder navigating a long clinical development road, a commercial leader trying to move physician behavior, or someone who just needs a reminder of why they got into this industry — Shaun's final piece of advice will stay with you: "Focus on that one patient you saw an impact on. Because that's the heart of everyone listening to this podcast."
Get new episodes of MedTech Mentor automatically
